New Drug Cuts Infant Hospitalizations Dramatically
RSV Protection: The Dawn of Proactive Infant Immunity and a Future Beyond Hospitalizations A staggering 80% reduction in hospitalizations due to Respiratory Syncytial Virus (RSV) following the introduction of nirsevimab – a monoclonal antibody – isn’t just a win for public health in Sweden and beyond. It’s a paradigm shift, signaling a future where proactive … Read more